{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:02:44Z","timestamp":1772996564676,"version":"3.50.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["19K07719"],"award-info":[{"award-number":["19K07719"]}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Galectin-3 is involved in various biological activities, including immune activations and fibrosis. Idiopathic inflammatory myopathies (IIMs) are autoimmune diseases of unknown aetiology, often complicated by interstitial lung disease (ILD). The aim of this study was to evaluate the expression of galectin-3 in sera and tissues of patients with IIM and assess the associations of galectin-3 with patient characteristics and disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Serum galectin-3 levels were significantly higher in IIM patients than in healthy controls. The serum galectin-3 levels positively correlated with serum levels of inflammatory markers and proinflammatory cytokines\/chemokines and the Myositis Intention-to-Treat Activity Index. Stratification analysis revealed that patients with IIM-associated ILD (IIM-ILD) had significantly higher levels of serum galectin-3 than those without IIM-ILD. In addition, patients with acute\/subacute interstitial pneumonia had significantly higher levels of serum galectin-3 than those with chronic interstitial pneumonia. Furthermore, serum galectin-3 levels in IIM-ILD patients correlated with the radiological assessments of parenchymal lung involvement and treatment response. Immunohistochemical analysis revealed that galectin-3 was expressed in inflammatory cells of myositis and dermatitis sections, whereas in ILD sections, galectin-3 was expressed in interstitial fibrosis and inflammatory cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Galectin-3 may be involved in the pathogenesis of inflammatory and fibrotic conditions in IIM and can serve as a potential biomarker of disease activity, especially in patients with IIM-ILD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa305","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T19:18:24Z","timestamp":1588792704000},"page":"322-332","source":"Crossref","is-referenced-by-count":11,"title":["Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity"],"prefix":"10.1093","volume":"60","author":[{"given":"Eri","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Faculty of Science and Engineering, Toyo University, Saitama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Gono","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama"},{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Radiology, Saitama Medical Center, Jichi Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Terai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kotake","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"2021010517014449800_keaa305-B1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1506827","article-title":"Inflammatory muscle diseases","volume":"373","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"2021010517014449800_keaa305-B2","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021010517014449800_keaa305-B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2021010517014449800_keaa305-B4","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"Kameda","year":"2005","journal-title":"J Rheumatol"},{"key":"2021010517014449800_keaa305-B5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"2021010517014449800_keaa305-B6","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"key":"2021010517014449800_keaa305-B7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/rheumatology\/kez301","article-title":"Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis\/dermatomyositis-interstitial lung disease","volume":"59","author":"Matsuda","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"2021010517014449800_keaa305-B8","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)","volume":"41","author":"Dong","year":"2017","journal-title":"Int J Mol Med"},{"key":"2021010517014449800_keaa305-B9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1535370215593826","article-title":"Galectin-3 in autoimmunity and autoimmune diseases","volume":"240","author":"de Oliveira","year":"2015","journal-title":"Exp Biol Med"},{"key":"2021010517014449800_keaa305-B10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.114.218370","article-title":"Functions of galectin-3 and its role in fibrotic diseases","volume":"351","author":"Li","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2021010517014449800_keaa305-B11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"2021010517014449800_keaa305-B12","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1074\/jbc.M117.783431","article-title":"Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells","volume":"292","author":"Colomb","year":"2017","journal-title":"J Biol Chem"},{"key":"2021010517014449800_keaa305-B13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","article-title":"The regulation of inflammation by galectin-3","volume":"230","author":"Henderson","year":"2009","journal-title":"Immunol Rev"},{"key":"2021010517014449800_keaa305-B14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-\u03b21-driven lung fibrosis by galectin-3","volume":"185","author":"Mackinnon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010517014449800_keaa305-B15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2332\/allergolint.O-06-449","article-title":"Role of galectin-3 in human pulmonary fibrosis","volume":"56","author":"Nishi","year":"2007","journal-title":"Allergol Int"},{"key":"2021010517014449800_keaa305-B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0961203317736144","article-title":"The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients","volume":"27","author":"Shi","year":"2018","journal-title":"Lupus"},{"key":"2021010517014449800_keaa305-B17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2021010517014449800_keaa305-B18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2021010517014449800_keaa305-B19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010517014449800_keaa305-B20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010517014449800_keaa305-B21","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1164\/rccm.2106157","article-title":"Acute interstitial pneumonia","volume":"165","author":"Ichikado","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010517014449800_keaa305-B22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2214\/ajr.169.4.9308447","article-title":"Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring","volume":"169","author":"Kazerooni","year":"1997","journal-title":"AJR Am J Roentgenol"},{"key":"2021010517014449800_keaa305-B23","volume-title":"Muscles: testing and function","author":"Kendall","year":"1993","edition":"4th edn."},{"key":"2021010517014449800_keaa305-B24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology"},{"key":"2021010517014449800_keaa305-B25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1346-8138.2011.01262.x","article-title":"Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients","volume":"38","author":"Ikeda","year":"2011","journal-title":"J Dermatol"},{"key":"2021010517014449800_keaa305-B26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3109\/14397595.2014.896494","article-title":"Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients","volume":"24","author":"Kang","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2021010517014449800_keaa305-B27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2021010517014449800_keaa305-B28","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: A new classification of adult autoimmune myositis","volume":"69","author":"Sen\u00e9cal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021010517014449800_keaa305-B29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cei.12445","article-title":"Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications","volume":"178","author":"Moran","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2021010517014449800_keaa305-B30","doi-asserted-by":"crossref","first-page":"18683","DOI":"10.3390\/ijms160818683","article-title":"Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies","volume":"16","author":"De Paepe","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2021010517014449800_keaa305-B31","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.24574","article-title":"Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways","volume":"60","author":"Filer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021010517014449800_keaa305-B32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/art.30118","article-title":"Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis","volume":"63","author":"Forsman","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021010517014449800_keaa305-B33","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021010517014449800_keaa305-B34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1159\/000490077","article-title":"Activation of TGF-\u03b21\/\u03b1-SMA\/Col I profibrotic pathway in fibroblasts by galectin-3 contributes to atrial fibrosis in experimental models and patients","volume":"47","author":"Shen","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"2021010517014449800_keaa305-B35","doi-asserted-by":"crossref","first-page":"e21879","DOI":"10.1002\/jbt.21879","article-title":"Galectin-3 contributes to vascular fibrosis in monocrotaline-induced pulmonary arterial hypertension rat model","volume":"31","author":"Wang","year":"2017","journal-title":"J Biochem Mol Toxicol"},{"key":"2021010517014449800_keaa305-B36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1513\/pats.201203-023AW","article-title":"The impact of TGF-\u03b2 on lung fibrosis","volume":"9","author":"Fernandez","year":"2012","journal-title":"Proc Am Thorac Soc"},{"key":"2021010517014449800_keaa305-B37","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/kes012","article-title":"Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"key":"2021010517014449800_keaa305-B38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","article-title":"Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis","volume":"35","author":"Xu","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2021010517014449800_keaa305-B39","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"2021010517014449800_keaa305-B40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","article-title":"Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis","volume":"20","author":"Ishikawa","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021010517014449800_keaa305-B41","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41598-017-01685-5","article-title":"Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study","volume":"7","author":"Oda","year":"2017","journal-title":"Sci Rep"},{"key":"2021010517014449800_keaa305-B42","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4049\/jimmunol.165.4.2156","article-title":"Human galectin-3 is a novel chemoattractant for monocytes and macrophages","volume":"165","author":"Sano","year":"2000","journal-title":"J Immunol"},{"key":"2021010517014449800_keaa305-B43","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/14397595.2015.1134392","article-title":"Initial limited three-level thin-section computed tomography scorings predict the prognosis of acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"26","author":"Kotani","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2021010517014449800_keaa305-B44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","article-title":"HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients","volume":"34","author":"Zou","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2021010517014449800_keaa305-B45","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/cbic.201600285","article-title":"Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition","volume":"17","author":"Delaine","year":"2016","journal-title":"Chembiochem"},{"key":"2021010517014449800_keaa305-B46","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1021\/acs.jmedchem.6b00957","article-title":"A selective galactose-coumarin-derived galectin-3 inhibitor demonstrates involvement of galectin-3-glycan interactions in a pulmonary fibrosis model","volume":"59","author":"Rajput","year":"2016","journal-title":"J Med Chem"},{"key":"2021010517014449800_keaa305-B47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","article-title":"Management of interstitial lung disease in patients with myositis specific autoantibodies","volume":"20","author":"Mecoli","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2021010517014449800_keaa305-B48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fmed.2019.00326","article-title":"Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment","volume":"6","author":"Hervier","year":"2019","journal-title":"Front Med"},{"key":"2021010517014449800_keaa305-B49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.berh.2016.04.006","article-title":"Connective tissue disease-related interstitial lung disease","volume":"30","author":"Demoruelle","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/322\/35433458\/keaa305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/322\/35433458\/keaa305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T08:25:52Z","timestamp":1610267152000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/1\/322\/5885286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,8]]},"published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa305","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,8,8]]}}}